Related Experiment Video

Updated: May 20, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Clinical validation of genetic markers for improved risk estimation

Thorsten Kessler1, Heribert Schunkert

  • 1Universität zu Lübeck, Medizinische Klinik II, Ratzeburger Allee 160, Lübeck, Germany.

European Journal of Preventive Cardiology
|July 18, 2012
PubMed

Insights

Predicting cardiovascular disease risk in asymptomatic individuals is imprecise. Integrating genetic data with traditional risk factors can improve risk prediction, especially for younger populations, enhancing primary prevention strategies.

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Preventive Cardiology

Background:

  • Cardiovascular disease (CVD) prevention is crucial, but risk prediction in asymptomatic individuals remains challenging.
  • Traditional risk assessment relies on modifiable factors (hypertension, dyslipidaemia) and family history, which may not fully capture genetic predisposition.
  • Genome-wide association studies (GWAS) have identified numerous genetic variants linked to CVD risk.

Purpose of the Study:

  • To evaluate the potential of incorporating genetic information into conventional risk scores for improving cardiovascular risk prediction.
  • To explore the utility of genetic markers in identifying lifetime CVD risk, particularly in younger, asymptomatic individuals.

Main Methods:

  • Review of existing literature on cardiovascular risk factors and genetic associations.
  • Analysis of the role of genome-wide association studies in identifying CVD-related genetic variants.
  • Assessment of the impact of adding genetic data to traditional cardiovascular risk assessment tools.

Main Results:

  • Genetic risk factors play a significant role in determining overall cardiovascular risk.
  • Integrating genetic information with conventional risk scores shows potential to enhance predictive accuracy.
  • Genetic markers may offer improved lifetime risk estimation for younger individuals where traditional scores often underestimate risk.

Conclusions:

  • Advances in cardiovascular genetics offer new avenues for improving CVD risk prediction.
  • Genetic information holds promise for refining primary prevention strategies for cardiovascular disease.
  • Personalized risk assessment incorporating genetic data could lead to more effective CVD prevention and treatment.

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations10:17

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations

Published on: November 3, 2010

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...